English

Navamedic applies for a listing on Oslo Børs

Report this content
Following a decision by the Board of Directors of Navamedic ASA, the Company will today apply for a listing on Oslo Børs. The Company expects that the listing application will be reviewed by the Board of Oslo Børs on March 29, 2006.
For further information, please contact:


CEO Øyvind S. Brekke, Navamedic
E-mail: oyvind.brekke@navamedic.com
Office: +47 67 11 25 40, Mobile: +47 91 19 81 64


CFO Jon W. Ringvold, Navamedic
E-mail: jon.ringvold@navamedic.com
Office: +47 67 11 25 44 Mobile: +47 99 15 85 34


 
About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl based medicines. Glucosamine is a generic active ingredient against osteoarthritis with a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world's population. Navamedic aims to become a leading company in the glucosamine industry by capitalising on proprietary production technology. The company's products will be sold through a network of sales, marketing and distribution partners in each country. Navamedic's product Glucomed® was approved as a medicine against osteoarthritis by the Swedish Medical Products Agency in August 2005.

Subscribe